News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chimerix, Inc. (CMRX) Looks To Rally Up $60 Million Partly To Pay For Drug Trial With Josh Hardy


5/20/2014 8:57:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In part to fund a drug trial initiated because of public pressure, Durham’s Chimerix will sell 6.2 million shares in hopes of raising at least $60 million. In filings made after the stock market closed Monday, Chimerix (Nasdaq: CMRX) announced it would sell the additional shares in part to fund a clinical trial to test its lead drug candidate, brincidofovir, on treating an adenovirus infection. Chimerix had focused its development of brincidofovir on treating double-stranded DNA (dsDNA) viral infections, including cytomegalovirus and adenovirus, that are common in transplant patients.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES